RT Journal Article
SR Electronic
T1 Viral load dynamics in transmissible symptomatic patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.02.20120014
DO 10.1101/2020.06.02.20120014
A1 Hitoshi Kawasuji
A1 Yusuke Takegoshi
A1 Makito Kaneda
A1 Akitoshi Ueno
A1 Yuki Miyajima
A1 Koyomi Kawago
A1 Yasutaka Fukui
A1 Yoshihiko Yoshida
A1 Miyuki Kimura
A1 Hiroshi Yamada
A1 Ippei Sakamaki
A1 Hideki Tani
A1 Yoshitomo Morinaga
A1 Yoshihiro Yamamoto
YR 2020
UL http://medrxiv.org/content/early/2020/06/04/2020.06.02.20120014.abstract
AB To investigate the relationship between viral load and secondary transmission in novel coronavirus disease 2019 (COVID-19), we reviewed epidemiological and clinical data obtained from immunocompetent laboratory-confirmed patients with COVID-19 at Toyama University Hospital. In total, 28 patients were included in the analysis. Median viral load at the initial sample collection was significantly higher in adults than in children and in symptomatic than in asymptomatic patients. Among symptomatic patients, non-linear regression models showed that the estimated viral load at onset was higher in the index (patients who transmitted the disease to at least one other patient) than in the non-index patients (patients who were not the cause of secondary transmission; median [95% confidence interval]: 6.6 [5.2–8.2] vs. 3.1 [1.5–4.8] log copies/μL, respectively). High nasopharyngeal viral loads around onset may contribute to secondary transmission of COVID-19.Article Summary Line High nasopharyngeal viral load around the onset may contributes to secondary transmission of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Board of University of Toyama (approval number: R2019167)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A